Innovative Medicine
-
Janssen Therapeutics Announces Latest Recipients Of LINCC™ Funding Initiative
Funded Programs Help Support Linkage To HIV/AIDS Care In Underserved Communities -
-
Janssen Biotech, Inc. Announces Collaborative Development And Worldwide License Agreement For Investigational Anti-Cancer Drug, PCI-32765
Compound in Development for Multiple B-Cell Hematologic Malignancies -
First Patient Enrolled In Therakos Phase Two Study For Treatment Of Graft-Versus-Host Disease
Study Will Examine The Use Of THERAKOS™ Photopheresis As A First-Line Therapy In Patients With Moderate-To-Severe Chronic GvHD -
Casey Abrams Announces Winners Of Inflammatory Bowel Disease Awareness Campaign After A National Vote
Season 10 American Idol Fan-Favorite Casey Abrams Will Recognize IBD Icons Winners Onstage During A Performance In Las Vegas -
-
Landmark Study Shows that Adding Rivaroxaban to Standard Antiplatelet Therapy Significantly Reduced Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
Rivaroxaban Used in Combination with Standard Therapy Reduced Cardiovascular Death by Over 30% -
Janssen Pharmaceutical Companies Launch Healthy Minds Initiative to Spur Neuroscience Collaboration and Support Millions Suffering from Brain Disorders
Healthy Minds Brings Together Researchers and Data to Solve Mysteries of the Brain, Commits Key Research Programs to Public Sector, and Addresses Stigma -
New Sirukumab (CNTO 136) Phase 2 Data Show Efficacy of Interleukin-6 Inhibitor across Multiple Dose Regimens in Treatment of Rheumatoid Arthritis
Subcutaneously Administered Monoclonal Antibody Improved Signs and Symptoms and Reduced Inflammation in Patients with Active Rheumatoid Arthritis